Evidence map›Paper›PMID 37711210›Full record

ArticleFrontiers in oncology2023

Comparison between regular additional endobiliary radiofrequency ablation and photodynamic therapy in patients with advanced extrahepatic cholangiocarcinoma under systemic chemotherapy.

Christian Möhring, Oliver Khan, Taotao Zhou, Farsaneh Sadeghlar, Robert Mahn, Dominik J Kaczmarek, Leona Dold, Marieta Toma, Milka Marinova, Tim R Glowka and 6 more

Abstract read
In one paragraph

Article in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Christian MöhringDepartment of Medicine I, University Hospital of Bonn, Bonn, Germany.
Oliver KhanDepartment of Medicine I, University Hospital of Bonn, Bonn, Germany.
Taotao ZhouDepartment of Medicine I, University Hospital of Bonn, Bonn, Germany.
Farsaneh SadeghlarDepartment of Medicine I, University Hospital of Bonn, Bonn, Germany.
Robert MahnDepartment of Medicine I, University Hospital of Bonn, Bonn, Germany.
Dominik J KaczmarekDepartment of Medicine I, University Hospital of Bonn, Bonn, Germany.
Leona DoldDepartment of Medicine I, University Hospital of Bonn, Bonn, Germany.
Marieta TomaDepartment of Pathology, University Hospital of Bonn, Bonn, Germany.
Milka MarinovaDepartment of Nuclear Medicine, University Hospital Bonn, Bonn, Germany.
Tim R GlowkaDepartment of Surgery, University Hospital of Bonn, Bonn, Germany.
Hanno MatthaeiDepartment of Surgery, University Hospital of Bonn, Bonn, Germany.
Steffen ManekellerDepartment of Surgery, University Hospital of Bonn, Bonn, Germany.
Jörg C KalffDepartment of Surgery, University Hospital of Bonn, Bonn, Germany.
Christian P StrassburgDepartment of Medicine I, University Hospital of Bonn, Bonn, Germany.
Tobias J WeismüllerDepartment of Medicine I, University Hospital of Bonn, Bonn, Germany.
Maria A Gonzalez-CarmonaDepartment of Medicine I, University Hospital of Bonn, Bonn, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and aims: Extrahepatic cholangiocarcinoma (eCCA) remains a malignancy with a dismal prognosis. The first-line standard of care includes systemic chemotherapy (SC) and biliary drainage through stenting. Endobiliary ablative techniques, such as photodynamic therapy (ePDT) and radio-frequency ablation (eRFA), have demonstrated feasibility and favorable survival data. This study aimed to compare the oncologic outcome in patients treated with SC and concomitant eRFA or ePDT. Method: All patients with eCCA were evaluated for study inclusion. Sixty-three patients receiving a combination of SC and at least one endobiliary treatment were retrospectively compared. Results: Patients were stratified into three groups: SC + ePDT (n = 22), SC + eRFA (n = 28), and SC + ePDT + eRFA (n = 13). The median overall survival (OS) of the whole cohort was 14.2 months with no statistically significant difference between the three therapy groups but a trend to better survival for the group receiving ePDT as well as eRFA, during SC (ePDT + SC, 12.7 months; eRFA + SC, 13.8 months; ePDT + eRFA + SC, 20.2 months; p = 0.112). The multivariate Cox regression and subgroup analysis highlighted the beneficial effect of eRFA on OS. Overall, combined therapy was well tolerated. Only cholangitis occurred more often in the SC + eRFA group. Conclusion: Additional endobiliary ablative therapies in combination with SC were feasible. Both modalities, eRFA and ePDT, showed a similar benefit in terms of survival. Interestingly, patients receiving both regimes showed the best OS indicating a possible synergism between both ablative therapeutic techniques.

Indexed as

biliary tractextrahepatic cholangiocarcinomaphotodynamic therapyradio frequency ablationsystemic chemotherapy

Identifiers

PMID37711210
PMCPMC10497756

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.